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The Journal of Immunology
Structural Basis for the Function of Complement Component
C4 within the Classical and Lectin Pathways of Complement
Sofia Mortensen,* Rune T. Kidmose,* Steen V. Petersen,† A´gnes Szila´gyi,‡
Zoltan Proha´szka,‡ and Gregers R. Andersen*
Complement component C4 is a central protein in the classical and lectin pathways within the complement system. During
activation of complement, its major fragment C4b becomes covalently attached to the surface of pathogens and altered self-
tissue, where it acts as an opsonin marking the surface for removal. Moreover, C4b provides a platform for assembly of the
proteolytically active convertases that mediate downstream complement activation by cleavage of C3 and C5. In this article, we
present the crystal and solution structures of the 195-kDa C4b. Our results provide the molecular details of the rearrangement
accompanying C4 cleavage and suggest intramolecular flexibility of C4b. The conformations of C4b and its paralogue C3b are
shown to be remarkably conserved, suggesting that the convertases from the classical and alternative pathways are likely to share
their overall architecture and mode of substrate recognition. We propose an overall molecular model for the classical pathway C5
convertase in complex with C5, suggesting that C3b increases the affinity for the substrate by inducing conformational changes
in C4b rather than a direct interaction with C5. C4b-specific features revealed by our structural studies are probably involved
in the assembly of the classical pathway C3/C5 convertases and C4b binding to regulators. The Journal of Immunology, 2015,
194: 5488–5496.
T
he lectin pathway (LP) and the classical pathway (CP)
(Fig. 1A) are two of the three main activation pathways
within the complement system that are involved in reso-
lution of infections, clearance of immune complexes, removal of
apoptotic/necrotic cells, and stimulation of adaptive immunity (1).
Both pathways are initiated by the binding of pattern recognition
molecules (PRMs) to molecular patterns presented by pathogens
or altered self-surfaces. In the CP, the PRM C1q recognizes IgG or
IgM present in immune complexes or bound to nonself surfaces,
pentraxins, and other ligands (2). Activation of the LP is based
on five PRMs— mannan-binding lectin, H/M/L-ficolin, and CL-L1/
K1—that bind specific carbohydrate structures or acetylated mole-
cules presented by pathogens (3). The PRMs in both pathways form
complexes with paralogous serine proteases; C1q binds the heter-
otetramer C1r2C1s2, and the LP PRMs bind mannan-binding lectin–
associated serine protease (MASP)-1 and MASP-2. Upon pattern
recognition, the associated proteases become activated, and C1s or
MASP-2 cleave C4 into C4b (195 kDa) and C4a (9 kDa). Although
the small fragment has no established biological function, C4b acts
as an opsonin and attaches to surface nucleophiles on the activator
through their reaction with the thioester (TE) exposed upon C4
cleavage (4). The zymogen C2 may then bind C4b to form the CP
proconvertase C4b2 (standardized notation for the C4b–C2 complex
and other complexes is used throughout), in which C2 is cleaved by
C1s, MASP-2, or MASP-1, and the C2b fragment is released. The
C4b2a complex (the CP C3 convertase) remains on the activator and
mediates downstream activation by cleaving C3 into C3b and C3a
(5). Strong amplification of C3 cleavage proceeds through the
alternative pathway (AP) via formation of the AP C3 convertase
C3bBb. At a high density of C3b on the activator surface, C3b may
combine with the C3 convertases, resulting in the CP and AP C5
convertases, C4b2a3b and C3bBb3b, respectively (6). In both
the C3 and the C5 CP convertase, C4b acts as the noncatalytic
substrate-binding subunit that presents the catalytic subunit C2a to
the substrate. In the CP C5 convertase, C4b also contacts C3b, and
they can even become covalently linked because C4b may offer
a nucleophile for the cleavage of the TE in nascent C3b (7).
C4 is paralogous to complement proteins C3 and C5 and shares up
to 30% sequence identity with the two proteins. However, maturation
of C4 is more complex compared with C3 and C5 and includes
generation of the three chains (a, b, and g) from the precursor and
the introduction of posttranslational modifications, including four
N- and one O-linked glycosylations and sulfation of three tyrosine
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residues (8, 9) (Fig. 1B). C4 exists in two isotypes: the products of
the two genes C4A and C4B. Although C4A and C4B differ in only
4-aa residues (C4A: P1120PCPVLD1125; C4B: L1120LSPVIH1125), they
display markedly different hemolytic activities and affinities toward
diverse substrates. Thus, C4A is more prone to attach to amine groups
of an activator, whereas C4B reacts preferentially with hydroxyl
groups (10, 11). Additionally, DNA and protein sequencing detected
23 polymorphic amino acid residues in both C4A and C4B (12).
Upon activation of C4, nascent C4b is expected to undergo con-
formational changes similar to those observed for C3/C3b, and the
role of C4b in the CP convertases is assumed to be analogous to that
of C3b in the AP convertases with respect to binding of the C3 and
C5 substrates (13). There have been several structural studies of the
AP C3 proconvertase and convertase (14–16), but it remains to be
shown whether C4b2 and C4b2a are organized in the same manner
or have additional unique features. There are also important dif-
ferences between C3b and C4b with regard to their regulation on
host cells and recognition by complement receptors (CRs). For
example, an important regulator of C4b is C4b binding protein
(C4BP), which acts as a cofactor for factor I (FI) cleavage of C4b
into C4c and C4d via generation of an intermediate product iC4b
(17–19); the main cofactor for C3b degradation, factor H (FH), is
not considered a regulator of C4b. Another striking example is
recognition of C3b/C4b and their degradation products by the CRs;
only CR1 has an established function as a receptor for C4b (20),
whereas there are five known receptors for C3b and its fragments
(1). Hence, although C3b and C4b provide the same platform for
substrates within the convertases, they are also highly distinct
molecules that share only some of their binding partners.
To provide the structural basis for the dissection of the multiple
functions of C4b, we determined the crystal structure of C4b at 4.2 A˚
resolution and characterized its solution structure by small angle
x-ray scattering (SAXS).
Materials and Methods
Generation and crystallization of C4b
Human C4 was purified from outdated plasma pools without any attempt to
separate isotypes C4A and C4B, essentially as described (21), although an
additional step of anion-exchange chromatography on a Mono Q column
(GE Healthcare) was added. To generate C4b, 50 mM Tris-HCl (pH 8.5),
30 mM glycine, 10 mM iodoacetamide, and 0.1% (w/w to C4) C1s
(Complement Technology) were added to the purified C4. The reaction was
incubated at 37˚C overnight, and 1% (w/w to C4) C1 Esterase Inhibitor
(Complement Technology) was added to the reaction mixture. The digest
was subsequently loaded onto a 9-ml Source 15Q column (GE Healthcare)
equilibrated in 20 mM HEPES-NaOH (pH 7.5), 200 mM NaCl and eluted
with an 80-ml 200–600-mM NaCl gradient. Fractions containing C4b were
pooled and dialyzed against 20 mM HEPES-NaOH (pH 7.5), 100 mM NaCl
overnight. For deglycosylation, C4b was made 50 mM in Tris-HCl (pH 7)
and 10% each (w/w to C4b) in GST-tagged EndoF1 and PNGase F. The
reaction mixture was incubated at 30˚C for 36 h, after which the endogly-
cosidases were removed by affinity chromatography on a GSTrap FF column
(GE Healthcare). The flow-through containing deglycosylated C4b was di-
alyzed against 20 mMHEPES-NaOH (pH 7.5), 100 mMNaCl overnight and
used for crystallization. Crystals of C4b were grown at 19˚C in sitting drops
made by mixing, in a 1:1:0.5 ratio, C4b at 4–5 mg/ml, reservoir solution
containing 7.5% (w/v) PEG8000, 0.4 M MgCl2, and 0.1 M Tris-HCl (pH 7),
and a crystal seed stock solution. Crystals were cryoprotected by soaking
them sequentially for 5–10 s in reservoir solution supplemented with 10, 20,
and 30% (v/v) PEG400 prior to flash cooling in liquid nitrogen.
Data collection and structure determination
Data were collected at the European Synchrotron Radiation Facility (ESRF)
(Grenoble, France) and processed with XDS (22). The structure was de-
termined with molecular replacement using Phaser (23) and two search
models based on macroglobulin (MG) domains 1–8 of C4 (RCSB Protein
Data Bank [PDB] entry 4FXK) superimposed on the equivalent domains
of C3b (RCSB PDB entry 2XWJ) and the TE domain derived from the
structure of C4dg (RCSB PDB entry 1HZF). Models were iteratively
refined in Phenix.refine (24) and manually rebuilt in the O software (25).
Atom positions were refined with simulated annealing and minimization,
whereas temperature factors were refined with grouped B-factors and
translation, libration, and screw-rotation groups. The two molecules in
the asymmetric unit were restrained to each other with tight positional
and loose B-factor noncrystallographic symmetry restraints. Electron-
density maps used for model building were improved by real-space
averaging. Figures were prepared with PyMOL v1.7.2.1 (http://www.
pymol.org). Coordinates and structure factors for the C4b crystal struc-
ture were deposited in the RCSB PDB (http://www.rcsb.org) under ac-
cession code 4XAM.
SAXS data collection and modeling
C4b not treated with endoglycosidases was used for SAXS experiments after
buffer exchange into 20 mM HEPES-NaOH (pH 7.5), 100 mM NaCl, 2 mM
MgCl2. Data were collected at the EMBL P12 beamline at PETRA III using
a PILATUS 2M pixel detector. Scattering of the C4b samples at concen-
trations of 10, 5, and 2.5 mg/ml was recorded doing 20 exposures of 0.045 s
with periods of 0.05 s for each sample in a temperature-controlled cell at 10˚C
with a path length of 1.5 mm. The sample-to-detector distance was 3.1 m,
covering a range of momentum transfer 0.0028, s, 0.45 A˚21 (s = 4psinu/l).
Normalization, radial averaging, buffer subtraction, and concentration cor-
rection of the data were done at the beamline by the automated pipeline (26).
Radius of gyration, scattering at zero angle (I(0)) were calculated for each
dataset using the ATSAS package (27) and compared. The two datasets
collected at the highest proteins concentrations (10 and 5 mg/ml) were
merged using ALMERGE (26). Data analysis and rigid body (RB) refine-
ment were done with ATSAS, using the data range 0 , s , 2.5 nm21.
Calculation of theoretical scattering profiles of atomic structures and their fits
to the experimental data were done with CRYSOL (28). Plots were prepared
with GraphPad Prism 5.03. The input model for CORAL RB refinement was
generated from the C4b crystal structure by addition of full biantenna Asn-
linked glycan derived from RCSB PDB entry 3RY6.
Isolation of O-linked glycosylated peptides
To isolate the C4A isoform, we obtained plasma from a healthy donor (54 y
old, female) with zero C4B gene copy number, as previously identified (29).
C4A was purified essentially as C4 from normal plasma but on smaller
columns. The conversion of C4A into C4Ac and C4Ad was performed
through incubation of C4A overnight at 37˚C in 50 mM Tris-HCl (pH 8.7),
30 mM glycine,10 mM iodoacetamide with C1s (1:500 w/w to C4), FI
(1:100 w/w to C4), and in-house purified C4BP (1:60 w/w to C4). The digest
was separated by cation-exchange chromatography on a Source 15S column
(GE Healthcare) equilibrated in 50 mM Tris-HCl (pH 7.6), 70 mM NaCl
(buffer A). C4Ac and C4Ad were eluted with a linear gradient from 70 to
400 mM NaCl in buffer A. Fractions containing C4Ad were pooled and
dialyzed into 50 mM NH4HCO3, 30 mM NaCl. To enable the analysis of
O-linked glycosylation, the purified C4Ad was incubated overnight at 37˚C
with 1:30 (w/w to C4Ad) porcine trypsin (Promega) and subjected to sub-
digestion using asparaginyl endopeptidase(Asn-C; R&D Systems) to obtain
smaller peptides compatible with mass spectrometry (MS) analysis. Prior to
digestion, Asn-C was activated by incubation in 50 mM sodium acetate
(pH 4), 100 mM NaCl for 2 h at 37˚C. Tryptic peptides were lyophilized and
resuspended in 100 mM citric acid (pH 5.5), 100 mM NaCl, 5 mM DTT;
activated Asn-C was added at an approximate ratio of 1:40 (w/w to C4Ad),
and the solution was allowed to incubate for 16 h at 37˚C. The digest was
acidified by the addition of trifluoroacetic acid (TFA), and peptides were
recovered using a StageTip (Thermo Scientific) containing C18 reverse-
phase material. The peptides were eluted using 90% (v/v) acetonitrile,
0.1% (v/v) TFA, lyophilized, resuspended in 100 mM Tris-HCl (pH 7.4),
500 mM NaCl, and applied to a 5-ml Jacalin/Agarose (InvivoGen) micro-
column equilibrated in the same buffer. The column was washed with
100 mM Tris-HCl (pH 7.4), 500 mM NaCl, and peptides subsequently were
eluted by the same buffer containing 20 mM a-methylgalactopyranoside.
The eluate was acidified, and peptides were recovered on a C18 StageTip and
eluted with a matrix solution of 2% (w/v) a-cyano-4-hydroxycinnamic acid,
70% (v/v) acetonitrile, 0.1% (v/v) TFA directly on the target plate for
MALDI-MS analysis. The MS analysis was performed using an autoflex III
Smartbeam instrument operated in reflector or linear mode and calibrated in
the mass range of 1000–3200 Da using Peptide Calibration Standard (both
from Bruker Daltonics).
Characterization of cysteine 1121
Purified C4Adwas incubated overnight at 37˚C with porcine trypsin (1:30 w/w
to C4Ad). The digest was subsequently acidified by the addition of TFA, and
peptides were separated by ultra performance liquid chromatography reverse-
phase chromatography using a BEH300 C18 column (2.1 mm 3 15 cm;
The Journal of Immunology 5489
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1.7 mm) operated by an ACQUITY UPLC System (Waters). The column
was developed at a flow rate of 300 ml/min using a 1% B/min linear gradient
of solvent B (90% v/v acetonitrile, 0.08% v/v TFA) in solvent A (0.1% v/v
TFA). Fractions were analyzed by MS using a-cyano-4-hydroxycinnamic
acid. The fraction containing the C4A isotype peptide (L1100-R1126) was
analyzed in both MS and tandem MS mode to validate the detected cys-
teinylation of C1121. The lyophilized fraction was resuspended in 50 mM
ammonium bicarbonate and 20 mM DTT and incubated at 37˚C for 20 min.
After that, the sample was made 40 mM in iodoacetamide and incubated at
room temperature for 20 min to allow for derivatization of free thiol groups.
The sample was acidified, and peptide was recovered with a StageTip
containing C18 reverse-phase material and eluted directly onto the target
plate using a-cyano-4-hydroxycinnamic acid, as described above.
Results
The architecture of C4b
We prepared crystallizable C4b of human complement component
C4 by cleaving purified C4 with C1s and trimming the N-linked
glycans with the endoglycosidases Endo F1 and PNGase F. The
resulting C4b formed fragile crystals with a typical size of 503 303
5 mm; after optimization of cryobuffers and mounting protocols, we
obtained a complete data set extending to 4.2 A˚ resolution (Fig. 1C,
Table I). The final model contained 1571 of 1637 C4b residues,
whereas untraceable regions encompassed residues 1231–1255
(prepronumbering of C4) in the TE domain, the C-terminal end of
the C4b a9-chain (residues 1414–1428), and the beginning of the
g-chain (residues 1454–1463). The final C4b model has Rwork/Rfree
values of 0.217/0.273 (Table I), which is quite favorable considering
the low resolution and the high Rmeas of the diffraction data. C4b is
organized into 12 domains, as previously described for C4 (21)
(Fig. 1D). The six MG domains (MG1–6) and the linker region
extensively interact with each other and form the core of the mol-
ecule. This represents the so-called “b-ring,” because it comprises
the entire b-chain; only the C-terminal region of the MG6 domain is
located in the a9-chain. The MG7 and MG8 domains are situated on
the top edge of the b-ring and form contacts with the MG2, MG3,
and MG6 domains. The complement C1r/C1s, Uegf, Bmp1 (CUB)
and TE domains are located on the long edge of the b-ring and
interact with MG2 and MG1, respectively (Fig. 1D). The TE, MG1,
MG4, and MG5 domains constitute the bottom of the molecule. The
C-terminal C345c domain is positioned at the opposite end of the
molecule, on top of the MG7–8 domains, and connected to the MG7
domain through a disulfide bridge. The two noncrystallographic
symmetry–related C4b molecules in our crystals vary in the
orientation of the C345c domain by a 5-A˚ translation and a 12˚
rotation, with no other noteworthy differences between the two
molecules.
The structural consequences of C4 cleavage
Our structure reveals the dramatic changes occurring upon release
of C4a and the subsequent conformational transition of nascent C4b
(Fig. 2, Supplemental Video 1). Overall, they are very similar to the
conformational changes occurring upon activation of C3 (see
below). Compared with C4, the major alterations in C4b are in
the positions and orientations of the MG8, CUB, and TE domains.
In C4, the TE is buried at the interface between the TE and MG8
domains (Fig. 2A); however, in C4b, it is highly exposed to nu-
cleophiles from either solvent or an activator that may cleave the
TE and form a covalent bond with Gln1013 (Fig. 2B). The location
of the TE glutamine suggests that the C4b molecule attaches to
activator surfaces with its bottom (the MG1, MG4, MG5, and TE
domains) located closest to the activator, whereas the C345c do-
main points away from the activator (Fig. 2B).
In C4, the MG8 and MG3 domains are held in position by the
anaphylatoxin domain; upon its release as C4a, the MG8 domain
rotates by 53˚ and translates by 29 A˚ (Fig. 2, Supplemental Video
1). The MG3 domain also rotates by 18˚ and establishes hydro-
phobic interactions with the relocated MG8 domain in C4b. The
FIGURE 1. The function of C4 in complement and the structure of C4b. (A) Proteolytic processing and function of C4 and C4b in the CP (involving C1s)
and the LP (involving MASP-1 and MASP-2). Active proteases are in bold font. C4b2a and C4b2a3b are the C3 and C5 convertases, respectively.
(B) Schematic representation of the chain and domain structure of C4 and C4b. Four N-linked (N226, N862, N1328, N1391) and one O-linked (T1244)
glycosylation sites are labeled. (C) The final model of C4b together with an omit 2mFo-DFc electron density map contoured at 1s calculated following
simulated annealing of a model with residues P1039-F1059 from the TE domain omitted. (D) The structure of C4b in two orientations. The position of the
TE glutamine residue is indicated by the red sphere marked “Q.” The domains are colored as (B).
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displacement of MG8 disrupts its contacts with the TE and CUB
domains, allowing these to rotate by 112 and 55˚ and move by 59
and 42 A˚, respectively, toward the MG1 and MG2 domains along
the long side of the b-ring core (Fig. 2, Supplemental Video 1). As
a consequence, the MG7 domain, which is connected to the CUB
domain, rotates by 35˚, relocates to form the “ceiling” of the MG2
and MG6 domains, and engages in new interactions with the MG8
domain (Figs. 1D, 2B). The MG7 domain has another important
function in C4b: it holds the newly generated N-terminal region of
the a9-chain (a9NT), consisting of residues 757–780. This region
encompasses several acidic residues (E763, E764, D768, E769,
E770, E771) believed to participate in the interaction of C4b with C2
(30). To reach this location, the a9NT region has to move out through
a narrow opening formed between the MG2, MG3, and MG6
domains and the linker region (Fig. 2, Supplemental Video 1). Fi-
nally, the C345c domain is translated by 10 A˚ and rotated by 42˚ as
a result of the loss of its contacts with the CUB domain. However,
the location of this domain is likely variable, as indicated by our
SAXS studies (see below). In summary, release of C4a induces
dramatic conformational changes in C4b that position the TE domain
in the vicinity of the MG1 domain and expose the TE to nucleo-
philes. The MG1–6 domains form a stable structural unit supporting
the movements of the MG7, MG8, CUB, and TE domains.
The solution structure of C4b
Crystallization of proteins can induce conformational artifacts by
crystal packing. Furthermore, because C4b could only be crystallized
upon trimming of the Asn-linked glycans, we decided to investigate
the solution conformation of C4b with glycans by performing SAXS
experiments (Supplemental Fig. 1). During RB refinement with
CORAL, four RBs were defined within C4b corresponding to all
MG domains, as well as the CUB, the TE, and the C345c domains
(Fig. 3A). With all RBs locked in the positions as in the C4b crystal
structure and modeling of residues not modeled in the crystal
structure, a mean x2 = 2.99 of the fit of the model to the experi-
mental SAXS data was observed. With four glycans added as
separate RBs, the mean x2 decreased to 2.12, justifying their ad-
dition. By allowing the CUB and C345c domains to move, mean x2
further decreased to 1.82, and the additional release of the TE do-
main gave a x2 value of 1.40. In the C4b crystal structure, a contact
between the MG1 and TE domains was observed; however, in the
CORAL models obtained with the above scenario, the TE do-
main separated from the MG1 domain. To explore this difference
between the crystal and solution structures, we evaluated three
restraints based on the MG1–TE domains contact with lengths of 6,
10, and 14 A˚, which gave rise to mean x2 values of 1.73, 1.51, and
1.43, respectively. This suggested that the contact observed in the
Table I. Statistics for data collection and model refinement
Data Collection and Processing
Beam line/l (A˚) ESRF ID23-1/0.9840
Space group P21
Unit cell parameters
a, b, c (A˚), b (˚) 121.50, 161.08, 131.60, 107.262
Resolution (A˚) 49.54–4.20 (4.39–4.20)
Rmeas (%) 28.5 (83.4)
I/sI 7.15 (2.56)
Completeness (%) 98.3 (99.3)
Redundancy 7.04 (7.15)
Refinement
Resolution (A˚) 49.54–4.20 (4.39–4.20)
No. reflections 34,849
Rwork/Rfree (%) 21.7/27.3 (30.3/39.4)
No. protein atoms 24,258
RMS deviations from ideality
Bond lengths (A˚)/angles (˚) 0.010/1.43
Average B values (A˚2) 127.7
Ramachandran plota (%)
Favored/allowed/outliers 91.65/8.07/0.29
The values in parentheses are for outer resolution shell. Rmeas¼
+hk1
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðn=ðn-1ÞÞ+nj¼1
Ihk1j2 ÆIhk1æ
q 
=+hk1+jIhk1j for the intensity of reflection
hkl measured n times.
R-factor¼

+hjjFoj2 kjFcjj=+hjFoj

, where Fo and Fc are the observed and
calculated structure factor, respectively, and k is a scaling factor. Rfree-factor is
identical to the R-factor on a subset of test reflections not used in refinement.
aValues given by MolProbity.
RMS, root mean square.
FIGURE 2. The structural changes accompanying activation of C4 and its transition to C4b. Overall views of C4 (RCSB PDB entry 4FXK) (A) and C4b
(B) with close-up views of the two regions, the MG8 domain (close-up view, solid box) and the a9NT (close-up view, dashed box) in the two states. The two
close-up views are related by a 180˚ rotation, because the domains shown in these views are located on opposite faces of C4 and C4b. The MG8 domain
undergoes a large rotation and translation upon release of C4a. The a9NT is inserted between the MG2, MG3, and the linker region in C4, whereas it has
moved out through the hole formed by these domains in C4b and now extends toward the MG7 domain. The C4 and C4b structures are superimposed on the
MG1–6 domains and shown separately. Green spheres mark the beginning and end of the MG8 domain. The a9NT region is displayed in yellow, and the
a9CT/sulfotyrosine region is displayed in magenta. The TE glutamine (“Q”) is shown as a red sphere.
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crystalline state is stabilized by crystal packing, whereas in solution
the two domains are separated slightly (Fig. 3C). As the final
SAXS-derived model of C4b, we present the CORAL solutions
derived from the scenario with the 14 A˚ MG1–TE contact restraint
described above with the best x2 = 1.41 (Fig. 3A, 3B).
The SAXS models indicate the structural organization of resi-
dues 1231–1255 within the TE domain that were not traceable in
the C4b crystal structure, suggesting its flexibility, as already pro-
posed by the structure of the C4b fragment C4dg (31). These res-
idues protrude from the TE domain in a roughly U-shaped exposed
loop in all SAXS models (Fig. 3A, 3D). In C4, this region is folded
into an ordered loop stabilized by interaction with the C4 CUB
domain. Another functionally important area in C4 is the a9CT/
sulfotyrosine region encompassing residues 1405–1427. In C4,
residues 1404–1415 form an a-helix that is followed by the three
sulfated tyrosines (Y1417, Y1420, Y1422) of importance for C4
interaction with C1s and MASP-2 (21, 32). In contrast, residues
1404–1413 adopt a random coil conformation in C4b, whereas the
residues 1414–1427 could not be traced. Our SAXS modeling
suggests that, in solution, the a9CT region runs across the MG7
domain roughly parallel to the a9NT (Fig. 3C). In addition to the
position of the TE domain, another major difference between
the crystal structure and the SAXS model is the reorientation of the
C345c domain by almost 90˚ (Fig. 3C). We tested the significance of
this by repeating the restrained CORAL scenario described above
where the C345c domain was fixed together with the MG domains
as observed in the crystal structure, but this increased the average x2
from 1.41 to 1.52, justifying release of the C345c domain during
refinement. In conclusion, our SAXS studies confirm the overall
conformation of C4b observed in the crystalline state but also
identified two significant deviations from the crystal conformation
in solution. Furthermore, the SAXS modeling suggests the approxi-
mate location of functionally important and exposed regions that
could not be modeled in the crystal structure because of flexibility.
Two posttranslational modifications in the C4 TE domain
Human C4A recovered from cerebrospinal fluid was identified to
contain an O-linked core 1 glycan (Gal-GalNAc-Thr; T-Ag) at
Thr1244 (8), meaning that it is exposed in the loop 1231–1255
discussed above (Fig. 3D). To confirm these findings, we subjected
the purified C4d fragment of C4A (C4Ad) to proteolytic cleavage
using both trypsin and Asn-C. To enrich for O-linked glycopeptides,
the generated peptides were fractionated by lectin-affinity chro-
matography using Jacalin/Agarose. Analysis of the isolated peptides
identified peaks representing the A1240-R1248 peptide (m/zcalc
895.5) modified by Gal-GalNAc (365.3 Da; m/zobs 1260.63) or by
its sialylated variant (656.6 Da; m/zobs 1551.52) (Supplemental Fig.
2A). To further validate that these ions indeed represented the
A1240-R1248 peptide, we subjected m/z 1260.63 to MS/MS anal-
ysis (Supplemental Fig. 2B). This analysis generated fragment ions
representing the peptide containing GalNAc only (m/z 1098.51) and
the peptide with no carbohydrate moiety (m/z 895.39). Moreover,
we could assign ions representing the y2 and y4 fragments of the
unglycosylated peptide (Supplemental Fig. 2B). Our data cannot
FIGURE 3. The SAXS model of C4b. The MG domains and the linker region are shown in cyan. N-linked glycans are displayed as blue sticks. Dummy atom
regions obtained during CORAL refinement representing the regions missing in the crystal structure are shown as spheres. The a9CT region is displayed in
magenta, the N-terminal end of the g-chain (gNT) is in cyan, and the 1231–1255 loop of the TE domain is orange. (A) Overview of the SAXS model of C4b,
the coloring reflects the RBs used during CORAL refinement. (B) The CRYSOL fit of the theoretical scattering calculated for the SAXS model (Imodel) to the
experimental scattering (Iexp) for the best model. (C) Differences in conformations of the C345c domain (left panel) and CUB–TE domains (right panel)
between the crystal structure and SAXS model of C4b. The CUB, TE, and C345c domains of the C4b crystal structure are colored light blue, gray, and brown,
respectively. Dummy atom modeling places the a9CT (magenta spheres) parallel to the a9NT, with its acidic residues displayed as sticks (left panel).
(D) Dummy atom model of the 1231–1255 loop in the TE domain in comparison with the ordered loop (gray) from the C4 crystal structure.
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conclusively distinguish between residues S1242 or T1244 as car-
rier of the O-linked glycan, but they are consistent with the finding
by Halim et al. (8) identifying Thr1244 as the modified residue.
Interestingly, this residue is almost strictly conserved, which points
to a functional importance of the O-linked glycan.
Additionally, human C4A encompasses an isotypic cysteine res-
idue at position 1121. Another isotypic residue of C4B, H1125, was
suggested to form an acyl-imidazole intermediate with the TE glu-
tamine upon C4B activation (33). This implies that a free thiol group
at position 1121 in C4A could play a role in TE cleavage or for-
mation of a de novo disulfide bridge with C1010 released from the
TE in C4b. To evaluate the status of residue 1121, we separated
tryptic peptides generated from C4Ad by reverse-phase chroma-
tography and analyzed the resulting fractions by MALDI-MS. One
fraction presented an ion of m/z 3194.89, corresponding to the
peptide encompassing C1121 (m/zcalc 3076.35) modified by cys-
teinylation (119 Da; m/zcalc 3194.89) (Supplemental Fig. 2C, upper
panel). To confirm this, we subjected the peptide to reduction and
alkylation, producing the S-carbamidomethylated peptide repre-
sented by m/z 3132.91 (Supplemental Fig. 2C, lower panel). The
position of the modifications was validated further by tandem MS
analysis, showing that C1121 is cysteinylated in human C4A. This
finding is consistent with previous studies showing that C4b gener-
ated by digestion of C4, which was isolated from pooled plasma and
expected to contain almost equivalent amounts of C4A and C4B, has
a maximum of one free thiol group/C4b molecule (34). Hence,
human C4A does not contain a free thiol, and C1121 and C1010 are
separated by 15 A˚ in C4b, further arguing that disulfide formation in
nascent C4b is unlikely to occur (Supplemental Fig. 2D).
Structural mapping of the C4 isoforms and allotypes
C4 is the most heterogeneous protein of the complement system.
In addition to the two isotypes of the C4 gene, C4A and C4B, 23
allotypes of the genes were reported. With the C4 and C4b structures
available, we can map these variants onto the two major functional
states of C4 (Fig. 4). This shows that 14 of these variable residues are
solvent accessible each in C4b and in C4 (additional variable resi-
dues are located in the C4a moiety). Eleven of the variants are lo-
cated in the TE domain, and seven of them are exposed in C4b
(Fig. 4). These variants are the basis for the serological distinction
between the Rodgers or Chido blood group Ags (35). Our analysis
suggests that eight of the variable isotypic and allotypic residues are
close to the activator in C4b (Fig. 4). Hence, similar to the dif-
ferential reactivity toward nucleophiles of the nascent TE in
C4A and C4B, the variation within surface-exposed residues
close to the activator might broaden the repertoire of inter-
actions that can occur between C4b and activators.
Discussion
During the last decade, a wealth of structures of complement proteins
has profoundly improved our understanding of structure–function
relationships within the complement system. C3 and C4 are im-
portant proteins of the complement cascade, because their proteo-
lytic fragments C3b and C4b act as opsonizing molecules, as well as
the central subunits in the C3/C5 convertases providing a platform
for bringing together the catalytic subunit and the substrate for
proteolysis. Although several crystal and solution structures in-
volving C3b are known, there has been a complete lack of structural
information concerning C4b. The present study provides this in-
formation and identifies the structural principles shared by C3b and
C4b, as well as several important C4b-specific features.
Structural similarity of C3b and C4b was expected, and com-
parison of our C4b structure with various structures containing C3b
indeed reveals a remarkable resemblance of the two paralogues. The
MG1–8 domains in C3b and C4b are arranged in a very similar
manner (Fig. 5A), which is likely to be dictated by the function
of the MG4, MG5, and MG7 domains in both C3b and C4b as
interactors with the substrate within the convertases (13) and their
common regulators (see below). Furthermore, the structural simi-
larity extends to the location of the CUB and TE domains observed
in our C4b crystal structure and all known C3b-containing crystal
structures. In particular, the MG1–TE interaction is preserved be-
tween crystal structures of C3b and C4b. Likewise, the presentation
of the a9NT region on the surface of the MG7 domain (Fig. 3C) is
shared between C3b and C4b.
The close conformational match between C3b and C4b further
strengthens the idea that the CP proconvertase C4b2 and convertase
C4b2a are similar in structure to their AP equivalents C3bB and
C3bBb and the fluid-phase convertase formed by cobra venom
factor (CVF) and Bb, CVFBb (13). Within the AP proconvertase,
the C3b a9NT region is sandwiched between the C3b MG7 domain
and factor B (14), and the virtually identical presentation of the a9NT
region in C4b on top of the MG7 domain suggests that this will apply
to the CP proconvertase as well (Supplemental Fig. 3A). This is in
accordance with reduced C2 binding to C4b carrying mutations in
two acidic clusters within the a9NT region (30). Additionally, in our
model of the CP proconvertase, the highly acidic and flexible a9CT/
sulfotyrosine region has the potential to interact with nearby posi-
tively charged areas of C2 (Supplemental Fig. 3A, 3B).
Our C4b structure also provides a means for investigating the
mysterious architecture of the CP C5 convertase C4b2a3b, in which
the presence of C3b shifts the specificity from C3 to C5. The SAXS-
based modeling of residues 1231–1255 in the TE domain of C4b
shows that the loop is highly exposed to the solvent (Fig. 3D). This
loop is known to be involved in the interaction of C4b with C3b
within the CP C5 convertase (7). Therefore, the exposure of these
residues and their accessibility for C3b might be necessary for
establishing contacts between C4b and C3b. Additionally, the strictly
conserved Ser1236 within the exposed loop can act as a nucleophile
FIGURE 4. The position of allotypic (yellow spheres) and isotypic (blue
spheres) residues mapped on the structure of C4b (upper right panel) and
C4 (upper left panel). Close-up views of the MG4-6 (lower left panel) and
the TE domain (lower right panel). The glutamine of the TE domain (Q) is
shown as a red sphere. The conformational change exposes some allotypic
residues and all the isotypic residues relatively close to the activator.
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attacking the TE in nascent C3b, leading to the formation of covalent
C4b–C3b heterodimers (7). The SAXS structure of C4b hints at how
C3b can be located in the CP C5 convertase because Ser1236 is the
primary contact point between C4b and C3b in this convertase. By
placing the cleaved TE of a C3b molecule roughly at the apex of the
exposed C4b loop, we can search for possible arrangements of the
C3b molecule relative to C4b (Supplemental Fig. 3D). We assume
that C3b does not change dramatically in conformation when it is
incorporated into the CP C5 convertase. This leads us to suggest
a model for the CP C5 convertase in which the longest principal
axes of C4b and C3b are arranged roughly in parallel (Fig. 4B,
Supplemental Fig. 3D). In the model, we chose to position the C3b
binding sites for FH complement control protein (CCP)1–4 and
CCP19–20 (Supplemental Fig. 3C) toward C4b, suggesting that
binding of these modules to C3b would interfere with a close ap-
proach of C3b and C4b in the CP C5 convertase, and additional
steric hindrance may exerted by the intervening CCP modules 5–18
of FH believed to be looping out between CCP4 and CCP19 (36,
37). The resulting model for the CP C5 convertase offers an ex-
planation for prior biochemical data showing that FH, in contrast to
factor B, inhibits lysis of erythrocytes (38) and that C3b covalently
bound to C4b is protected from FH-dependent FI degradation (39).
However, our model for the CP C5 convertase must be considered
with caution, keeping in mind that conformation of the loop con-
taining the C4b–C3b contact point (Ser1236) is modeled by the use
of low-resolution SAXS data. If this loop adopts a radically different
conformation in activator-bound C4b, the suggested parallel orien-
tation of C3b and C4b in the CP C5 convertase may not be possible.
An important feature of our CP C5 convertase model is that the
C3b molecule cannot obtain direct contact with C5 because of the
proximity between the two TE domains of C3b and C4b, suggesting
that C3b alters the substrate specificity from C3 to C5 solely by
altering the conformation of the C4b2a complex. An overall pu-
tative model of the substrate-bound C5 convertase is displayed in
Fig. 5B; the MG6 domain of C3b is close to the MG3 and MG8
domains of C4b. Because the latter two domains are adjacent to
the substrate-binding C4b domains MG4 and MG7, respectively, it
is conceivable that an allosteric effect leading to higher C5 affinity
could be transmitted through C3b contacts with these C4b domains.
Based on the ability of both anti-C4 and anti-C3 Abs to inhibit
substrate binding by the CP C5 convertase, it was suggested pre-
viously that both C4b and C3b form direct contact with C5 (6).
However, our model is also consistent with these data: the anti-C3
Abs might simply interfere with the C3b–C4b interaction proposed
in this article.
By combining our C4b and CVF-C5 structures, we suggest that
the C4b-binding area for the substrates C3 and C5 is within the
domains MG4, MG5, and MG7. This suggestion is supported by
studies showing that changes in the two variant residues in theMG5
domain of C4b, R477, and P478 (Fig. 4), to tryptophan and leu-
cine, respectively, cause defects in C5 binding by the CP C5
convertase (40, 41), and alanine scanning of residues in their vi-
cinity also results in mutant C4b molecules impaired in CP C5
convertase activity (42). Moreover, the a9CT is also located near
C5 in our substrate-convertase model (Fig. 5B), which suggests
that, as in the C4:MASP-2 complex, the a9CT region may bridge
the substrate and the catalytic subunit. In summary, the structures
of C3b and C4b are surprisingly similar. This allows us to com-
bine structural studies of the AP convertases with biochemical and
genetic data on the CP proteins and convertases. Thereby, we are
able to propose overall working models for the CP convertases.
The C4b a9CT/sulfotyrosine region is an extremely acidic re-
gion harboring 11 negative charges within residues 1405–1427.
We and other investigators provided data showing that it facili-
tates C1s/MASP-2 recognition of C4 (21, 43) by acting as electro-
static “Velcro” between the SP domain of the protease and the C4
anaphylatoxin domain. However, the observed changes within the
a9CT region in C4b compared with C4 prompted us to speculate
on other functions for this C4-specific region. Our SAXS mod-
eling indicated that the a9CT region is associated with the MG7
domain and is located close to the C345c domain of C4b and the
acidic a9NT region (Fig. 3C). Again, the low resolution of the
SAXS data means that suggestions based on the resulting RB
models must be treated with caution. Even if the conformation of
the a9CT region is different from that proposed by SAXS, this
highly negatively charged and flexible region has a length and
flexibility that probably enable it to interact with C2, C2a, con-
vertase substrates, and even regulators.
Our crystal and SAXS structures differ with respect to the lo-
cation of the C345c, TE, and CUB domains, suggesting that C4b
harbors some degree of flexibility, which may be a prerequisite for
the function of the molecule. The flexibility of the C345c domain is
a well-known phenomenon, because reorientation of this domain is
also observed in structures involving C3b (14, 15, 44). In C4/C4b,
FIGURE 5. A highly conserved conformation of C3b/C4b and the model of the CP C5 convertase complex. (A) Comparison of the C3b (RCSB PDB
entry 2I07) and C4b crystal structures demonstrates the striking similarities in their conformation. The structures were superimposed on the MG1–5
domains. (B) The model of the CP/LP C5 convertase in complex with C5 built based on combining the structures of C4b, the C3b–FH CCP1–4 complex
(RCSB PDB entry 2WII), the C3b–FH CCP19–20 complex (RCSB PDB entry 4ONT), the CVF–C5 complex (RCSB PDB entry 3PVM), the C3bBb
complex (RCSB PDB entry 2WIN), and C2a (RCSB PDB entry 2ODP). The C3b molecule (in blue) was placed by positioning the glutamine (Q) of the C3b
TE domain at the apex of the C4 loop and then rotating C3b such that its FH binding sites are facing C4b (see also Supplemental Fig. 3C, 3D). The
proximity of the a9CT region to both C2a and C5 is shown (right panel).
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this flexibility is probably required for its multiple functions be-
cause it is both a carrier of C2/C2a protease in the (pro)convertases
and a binding site for MASP-2 and C1s proteases during C4
cleavage (21). The ability of the TE domain to dissociate from
the MG1 domain, as observed in the SAXS structure, may support
C4b function as an opsonin by improving its chance for covalent
attachment to the myriad of activator surfaces that it encounters.
Very recent solution structures of C3b and C3(H2O) in 137 mM
NaCl indicated that the TE domain of C3b can separate by up to
60 A˚ from the MG1 domain, whereas a compact conformation re-
sembling the C3b crystal conformation was observed in 50 mM
NaCl (45). It was suggested that the low salt concentrations used for
crystallization of C3b induced the compact conformation with the
TE–MG1 contact. We observed the opposite trend; our SAXS
modeling of C4b in solution indicates that the TE domain can move
slightly away from the MG1 domain in the presence of 100 mM
NaCl, whereas C4b exhibits the MG1–TE interaction inside
crystals grown in the presence of 400 mM MgCl2. Cofactor-
assisted FI cleavage presumably requires a rather fixed conforma-
tion of C3b and C4b to dock C3b/C4b, the regulator, and FI
simultaneously into a productive complex (46). Therefore, the crystal
structures of C3b and C4b are likely to resemble a substrate con-
formation for cofactor-assisted FI degradation. This does not exclude
that the TE and CUB domains may be more or less separated from
the MG domains in other functional states of C3b and C4b.
Binding of FH CCP1–4 domains relies on interaction with the
C3b a9NT region, the MG1, MG2, MG6, and MG7 domains, and
the CUB and TE domains (46). Thereby, FH provides a platform
for positioning FI correctly relative to the C3b CUB domain for
subsequent cleavage, and this binding mode probably applies to
membrane cofactor protein (MCP) and decay acceleration factor
(DAF) as well (46). The cofactors themselves also have a conserved
structure. Usually, three consecutive CCP domains are required for
cofactor activity, and these three are linked in an almost linear
structure (47), whereas a bend occurs between the third and the
following CCP domains, which may not be required for cofactor
activity. The high conservation between C3b and C4b, the con-
served positions of FI cleavage sites in the CUB domains of C3b
and C4b, and the conserved structure of the regulators led us to
suggest a simplistic model for the interaction of C4b with its reg-
ulators (Supplemental Fig. 3E). This suggests that cofactors (C4BP,
MCP, CR1, MCP, the vaccinia virus complement control protein
VCP, and the rodent specific Crry) for FI degradation bind to C4b
in a manner similar to that observed in the C3b–FH complex. In
agreement with this proposal, C4c encompassing all of the MG
domains and the a9NT region binds only three times weaker than
does C4b to C4BP (48). In the proposed binding mode, the CCP1 and
CCP2 domains of C4b regulators would align with the C4b a9NT
region, like in the C3b–FH complex, and significantly contribute to
binding of the whole regulator molecule to C4b. In addition to the
a9NT, the nearby highly acidic a9CT/sulfotyrosine region of C4b
might play a role by interacting with basic residues in a regulator’s
CCP1–CCP2 domains (Supplemental Fig. 3D). All C4b cofactors
indeed have several lysines and arginines that would face the a9CT
and a9NT regions in a C3b-FH–like binding mode. The importance
of a cluster of basic residues exactly in the C4BP CCP1–CCP2
domains for cofactor activity against C4b, as well as the strong
electrostatic nature of the intermolecular interaction C4b–C4BP, were
shown earlier by mutagenesis and binding studies (49). Another
regulator of C4b, DAF, likewise contains positively charged residues
in its CCP2 domain and the linker between CCP2 and CCP3 that
might interact with the two aforementioned acidic C4b regions.
In conclusion, determination of both the crystal and solution
structures of C4b confirms the anticipated unifying structural prin-
ciples for C3b and C4b, supporting their shared functions as opsonins
and as platforms for binding the catalytic subunit and substrates in
convertases. Additionally, our results highlight the flexibility of the
TE domain loop 1231–1255 and the sulfotyrosine-containing a9CT
region specific to C4 and suggest important functions of these ele-
ments within the CP convertases. Our study sets the scene for dis-
secting structural requirements of C4b binding of C2/C2a, the role of
C3b in shifting the specificity of the CP C3 convertase to C5, and the
recognition of C4b by DAF and the FI cofactors CR1, C4BP, Crry,
and MCP.
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